Salubris (002294.SZ): Drugs including Fulitan and Xinliting remain included in the National Reimbursement Drug List

Zhitong Finance APP news, Salubris (002294.SZ) announced that the company's drugs Fuletan (Alisartan Isopropyl Ester and Amlodipine Tablets) and Xinliting (Fuglitin Benzoate Tablets) have successfully renewed their contracts, and Ennaluo (Enarodustat Tablets) has successfully negotiated a new indication and been retained in the "National Drug Catalog for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2026)." Inclusion in the medical insurance catalog will help further enhance the accessibility of the relevant drugs and expand the market size.